← Search & browse all drugs
NERVOUS SYSTEM › ANTI-PARKINSON DRUGS › DOPAMINERGIC AGENTS › Other dopaminergic agents
budipine
N04BX03
Forms & Strengths
- Extended-release capsules: 5 mg
- Extended-release capsules: 10 mg
- Extended-release capsules: 20 mg
Adult Dosing
- Initial dose: 5 mg once daily, titrated slowly over several weeks
- Maintenance dose: 10 mg to 20 mg once daily
- Maximum daily dose: 20 mg/day
Pediatric Dosing
- Safety and efficacy in pediatric patients have not been established
Indications
- Treatment of Parkinson's disease, either as monotherapy or as an adjunct to levodopa
Mechanism of Action
- Non-competitive NMDA receptor antagonist
- Moderate anticholinergic activity
- Mild inhibition of monoamine reuptake, enhancing dopaminergic neurotransmission
Contraindications
- Hypersensitivity to budipine
- Severe hepatic impairment
- Severe renal impairment
- History of severe cardiac arrhythmias or prolonged QT interval
- Concomitant use of other drugs known to prolong the QT interval
Adverse Reactions
- Dizziness
- Dry mouth
- Visual disturbances (blurred vision)
- Orthostatic hypotension
- Nausea and gastrointestinal distress
- Psychiatric symptoms (hallucinations, confusion in elderly patients)
- QT interval prolongation
Drug Interactions
- Antiarrhythmic drugs (Class IA and III) due to risk of additive QT prolongation
- Other centrally active anticholinergic drugs, leading to enhanced anticholinergic side effects
- Alcohol and central nervous system depressants, increasing sedative effects
Curated Content: Needs Vetting Before Put to Clinical Use